Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice
- First Online:
- 40 Downloads
To validate the immune protective efficacy of pORF5 DNA vaccine and to analyze potential mechanisms related to this protection. In this study, pORF5 DNA vaccine was constructed and evaluated for its protective immunity in a mouse model of genital chlamydial infection. Groups of BALB/c mice were immunized intranasally with pORF5 DNA vaccine. Humoral and cell mediated immune responses were evaluated. The clearance ability of chlamydial challenge from the genital tract and the chlamydia-induced upper genital tract gross pathology and histopathological characterization were also detected. The results showed that the total and the IgG2a anti-pORF5 antibody levels in serum were significantly elevated after pcDNA3.1-pORF5 vaccination, as were the total antibody and IgA levels in vaginal fluids. pcDNA3.1-pORF5 induced a significantly high level of Th1 response as measured by robust gamma interferon (IFN-γ). Minimal IL-4 was produced by immune T cells in response to the re-stimulation with pORF5 protein or the inactive elementary body in vitro. pcDNA3.1-pORF5-vaccinated mice displayed significantly reduced bacterial shedding upon a chlamydial challenge and an accelerated resolution of infection. 100% of pcDNA3.1-pORF5 vaccinated mice successfully resolved the infection by day 24. pcDNA3.1-pORF5-immunized mice also exhibited protection against pathological consequences of chlamydial infection. The stimulated index was significantly higher than that of mice immunized with pcDNA3.1 and PBS (P<0.05). Together, these results demonstrated that immunization with pORF5 DNA vaccine is a promising approach for eliciting a protective immunity against a genital chlamydial challenge.
KeywordsChlamydia trachomatis pORF5 DNA vaccine immune protection Th1 immune response
Unable to display preview. Download preview PDF.
- 6.Igietseme J U, Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complex. Infect Immun, 2000, 68(12): 6798–6806, 11083798, 10.1128/IAI.68.12.6798-6806.2000, 1:CAS:528:DC%2BD3MXjslCktLo%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 8.Zhang D J, Yang X, Shen C, et al. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology, 1999, 96(2): 314–321, 10233711, 10.1046/j.1365-2567.1999.00682.x, 1:CAS:528:DyaK1MXhtFOisrs%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 10.Donati M, Sambri V, Comanducci M, et al. DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine, 2003, 21(11–12): 1089–1093, 12559784, 10.1016/S0264-410X(02)00631-X, 1:CAS:528:DC%2BD3sXmt1ahsg%3D%3DCrossRefPubMedGoogle Scholar
- 12.Li Z, Zhong Y, Lei L, et al. Antibodies from women urogenitally infected with C. trachomatis predominantly recognized the plasmid protein pgp3 in a conformation-dependent manner. BMC Microbiol, 2008, 8: 90–102, 18541036, 10.1186/1471-2180-8-90, 1:CAS:528:DC%2BD1cXotlCisrk%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 16.Holland M J, Bailey R L, Conway D J, et al. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin Exp Immunol, 1996, 105(3): 429–435, 8809130, 10.1046/j.1365-2249.1996.d01-792.x, 1:STN:280:DyaK28vgsV2qsg%3D%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 17.Faal N, Bailey R L, Sarr I, et al. Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection. Clin Exp Immunol, 2005, 142(2): 347–353, 16232223, 10.1111/j.1365-2249.2005.02917.x, 1:STN:280:DC%2BD2Mrls1SktA%3D%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 21.Darville T, Andrews C W Jr, Rank R G. Does inhibition of tumor necroses factor alpha affect chlamydial genital tract infection in mice and guinea pigs? Infect Immun, 2000, 68(9): 5299–5305, 10948158, 10.1128/IAI.68.9.5299-5305.2000, 1:CAS:528:DC%2BD3cXmtVektr0%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 22.Perfettini J L, Darville T, Gachelin G, et al. Effect of Chlamydia trachomatis infection and subsequent tumor necrosis factor alpha secretion on apoptosis in the murine genital tract. Infect Immun, 2000, 68(4): 2237–2244, 10722625, 10.1128/IAI.68.4.2237-2244.2000, 1:CAS:528:DC%2BD3cXitFels7w%3DCrossRefPubMedCentralPubMedGoogle Scholar
- 23.Wang S, Fan Y, Brunham R C, et al. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol, 1999, 29(11): 3782–3792, 10556835, 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B, 1:CAS:528:DyaK1MXnt1Ogurc%3DCrossRefPubMedGoogle Scholar
- 28.Cotter T W, Meng Q, Shen Z L, et al. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun, 1995, 63(12): 4704–4714, 7591126, 1:CAS:528:DyaK2MXpslClsLs%3DPubMedCentralPubMedGoogle Scholar